Daxor (NASDAQ:DXR) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Daxor (NASDAQ:DXR) posted its quarterly earnings data on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07), FiscalAI reports. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $2.80 million.

Daxor Stock Down 1.2%

Shares of NASDAQ DXR traded down $0.12 during trading on Monday, reaching $10.08. 872 shares of the stock traded hands, compared to its average volume of 6,900. Daxor has a 52-week low of $8.56 and a 52-week high of $14.76. The company has a 50-day moving average of $10.38 and a 200-day moving average of $10.56.

Institutional Investors Weigh In On Daxor

A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. bought a new position in shares of Daxor Corporation (NASDAQ:DXR) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned 0.18% of Daxor as of its most recent SEC filing. 1.34% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.